Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $43.40.

Several equities research analysts have recently weighed in on DMRA shares. Evercore started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price objective for the company. UBS Group started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. They set a “buy” rating and a $45.00 price objective for the company. Guggenheim reissued a “buy” rating and set a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Royal Bank Of Canada started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They set an “outperform” rating and a $40.00 price objective for the company. Finally, Lifesci Capital raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, February 2nd.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at about $40,000. Geode Capital Management LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at about $266,000. Virtu Financial LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the third quarter valued at about $49,000. Sigma Planning Corp purchased a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at about $334,000. Finally, Two Sigma Investments LP purchased a new stake in Damora Therapeutics, Inc. Common Stock during the third quarter valued at about $76,000. 14.20% of the stock is owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Price Performance

Shares of DMRA opened at $24.60 on Monday. The firm’s 50 day moving average is $25.59 and its 200-day moving average is $24.17. The stock has a market capitalization of $1.51 billion, a P/E ratio of -3.58 and a beta of 1.50. Damora Therapeutics, Inc. Common Stock has a 12-month low of $2.45 and a 12-month high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.23). As a group, equities research analysts forecast that Damora Therapeutics, Inc. Common Stock will post -0.95 EPS for the current fiscal year.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.